Sequential development of interleukin 2–dependent effector and regulatory T cells in response to endogenous systemic antigen
Top Cited Papers
Open Access
- 14 November 2005
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 202 (10) , 1375-1386
- https://doi.org/10.1084/jem.20050855
Abstract
Transfer of naive antigen-specific CD4+ T cells into lymphopenic mice that express an endogenous antigen as a systemic, secreted protein results in severe autoimmunity resembling graft-versus-host disease. T cells that respond to this endogenous antigen develop into effector cells that cause the disease. Recovery from this disease is associated with the subsequent generation of FoxP3+CD25+ regulatory cells in the periphery. Both pathogenic effector cells and protective regulatory cells develop from the same antigen-specific T cell population after activation, and their generation may occur in parallel or sequentially. Interleukin (IL)-2 plays a dual role in this systemic T cell reaction. In the absence of IL-2, the acute disease is mild because of reduced T cell effector function, but a chronic and progressive disease develops late and is associated with a failure to generate FoxP3+ regulatory T (T reg) cells in the periphery. Thus, a peripheral T cell reaction to a systemic antigen goes through a phase of effector cell–mediated pathology followed by T reg cell–mediated recovery, and both require the growth factor IL-2.Keywords
This publication has 61 references indexed in Scilit:
- Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trialBlood, 2004
- In Vivo Instruction of Suppressor Commitment in Naive T CellsThe Journal of Experimental Medicine, 2004
- Homeostatic Expansion of T Cells during Immune Insufficiency Generates AutoimmunityPublished by Elsevier ,2004
- Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 The Journal of Experimental Medicine, 2003
- Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administrationJournal of Autoimmunity, 2003
- Natural versus adaptive regulatory T cellsNature Reviews Immunology, 2003
- In Vitro Generation of Interleukin 10–producing Regulatory CD4+ T Cells Is Induced by Immunosuppressive Drugs and Inhibited by T Helper Type 1 (Th1)– and Th2-inducing CytokinesThe Journal of Experimental Medicine, 2002
- The enemy within: keeping self-reactive T cells at bay in the peripheryNature Reviews Immunology, 2002
- lnterleukin-2 programs mouse αβ T lymphocytes for apoptosisNature, 1991
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985